Market Research Logo

Merck & Co., Inc. - Product Pipeline Review - 2016

Merck & Co., Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Merck & Co., Inc. - Product Pipeline Review - 2016’, provides an overview of the Merck & Co., Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc.
  • The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Merck & Co., Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Merck & Co., Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Merck & Co., Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Merck & Co., Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Merck & Co., Inc. Snapshot
Merck & Co., Inc. Overview
Key Information
Key Facts
Merck & Co., Inc. - Research and Development Overview
Key Therapeutic Areas
Merck & Co., Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Merck & Co., Inc. - Pipeline Products Glance
Merck & Co., Inc. - Late Stage Pipeline Products
Merck & Co., Inc. - Clinical Stage Pipeline Products
Merck & Co., Inc. - Early Stage Pipeline Products
Merck & Co., Inc. - Drug Profiles
(elbasvir + grazoprevir)
asenapine maleate
bezlotoxumab
desloratadine
diquafosol tetrasodium
fosaprepitant dimeglumine
insulin glargine
narlaprevir
pembrolizumab
(actoxumab + bezlotoxumab)
(atorvastatin calcium + ezetimibe)
(ceftolozane sulfate + tazobactam sodium)
(cilastatin sodium + imipenem + relebactam)
(doravirine + lamivudine + tenofovir disoproxil fumarate)
actoxumab
anacetrapib
corifollitropin alfa
doravirine
fidaxomicin
letermovir
odanacatib
omarigliptin
posaconazole
solithromycin
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract
tedizolid phosphate
V-212
V-920
verubecestat
vibegron
vorinostat
(grazoprevir + MK-3682 + MK-8408)
BQ-123
dalotuzumab
elbasvir + grazoprevir + MK-3682
grazoprevir
lomerizine
lonafarnib
mirtazapine ODT
MK-1029
MK-2206
MK-2206 + selumetinib sulfate
MK-7622
MK-8521
MK-8628
samatasvir
temozolomide
V-114
MK-3682
vorapaxar sulfate
CB-618
insulin human
MK-0752
MK-1075
MK-1248
MK-2048
MK-2248
MK-4166
MK-7680
MK-8189
MK-8242
MK-8291
MK-8408
MK-8507
MK-8591
MK-8666
MK-8723
MK-8876
Monoclonal Antibody for Autoimmune Diseases
NB-1008
rituximab biosimilar
Small Molecule 1 for Human Cytomegalovirus Infection
Small Molecule 2 for Human Cytomegalovirus Infection
V-160
V-180
BNC-375
CB-027
chikungunya (viral like particles) vaccine
DORA-12
Drug to Inhibit 11Beta-HSD1 for Hypertension
ETP-142
GP-4
GRA-1
J8-CRM197
mDX-400
MK-0429
MK-1966
MK-4256
MK-8267
MK-8745
MK-8825
MK-8970
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia
Monoclonal Antibody for Cancer
MRK-003
MRK-1777
MRLB-11055
Proteins for Cancer, Autoimmune and Inflammatory diseases
PTC-512
PTC-725
PTC-971
PyP-1
respiratory syncytial virus vaccine
SCH-412348
SCH-546738
Small Molecule 3 for Human Cytomegalovirus Infection
Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders
Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes
Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection
Small Molecule to Inhibit ROMK for Hypertension and Heart Failure
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis
Small Molecules for Undisclosed Indications
Small Molecules to Agonize GPR119 for Metabolic Disorders
Small Molecules to Agonize M1 for Alzheimer’s Disease
Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease
Small Molecules to Block Cav2.2 Channel for Chronic Pain
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases
Small Molecules to Inhibit DGAT1
Small Molecules to Inhibit DHFR for Septicaemia
Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours
Small Molecules to Inhibit Prolyl Hydroxylase for Anemia
Small Molecules to Inhibit Renin for Hypertension
THPP-1
TROX-1
XEN-445
XL-499
Drug to Target GPCR for Undisclosed Indication
Kibdelomycin A
MK-8133
Monoclonal Antibodies for Undisclosed Indication
Monoclonal Antibody for Neurology
SCH-722984
Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication
Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections
Small Molecules to Inhibit IRAK4 for Inflammatory Diseases
Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation
Small Molecules to Inhibit NS5A for Hepatitis C
Small Molecules to Inhibit PPI for Undisclosed Indication
Undisclosed Biosimilars
Merck & Co., Inc. - Pipeline Analysis
Merck & Co., Inc. - Pipeline Products by Target
Merck & Co., Inc. - Pipeline Products by Route of Administration
Merck & Co., Inc. - Pipeline Products by Molecule Type
Merck & Co., Inc. - Pipeline Products by Mechanism of Action
Merck & Co., Inc. - Recent Pipeline Updates
Merck & Co., Inc. - Dormant Projects
Merck & Co., Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Merck & Co., Inc. - Company Statement
Merck & Co., Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Merck & Co., Inc., Key Information
Merck & Co., Inc., Key Facts
Merck & Co., Inc. - Pipeline by Indication, 2016
Merck & Co., Inc. - Pipeline by Stage of Development, 2016
Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016
Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016
Merck & Co., Inc. - Partnered Products in Pipeline, 2016
Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016
Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Merck & Co., Inc. - Pre-Registration, 2016
Merck & Co., Inc. - Phase III, 2016
Merck & Co., Inc. - Phase II, 2016
Merck & Co., Inc. - Phase I, 2016
Merck & Co., Inc. - Preclinical, 2016
Merck & Co., Inc. - Discovery, 2016
Merck & Co., Inc. - Pipeline by Target, 2016
Merck & Co., Inc. - Pipeline by Route of Administration, 2016
Merck & Co., Inc. - Pipeline by Molecule Type, 2016
Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2016
Merck & Co., Inc. - Recent Pipeline Updates, 2016
Merck & Co., Inc. - Dormant Developmental Projects,2016
Merck & Co., Inc. - Discontinued Pipeline Products, 2016
Merck & Co., Inc., Subsidiaries
List of Figures
Merck & Co., Inc. - Pipeline by Top 10 Indication, 2016
Merck & Co., Inc. - Pipeline by Stage of Development, 2016
Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016
Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016
Merck & Co., Inc. - Partnered Products in Pipeline, 2016
Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016
Merck & Co., Inc. - Pipeline by Top 10 Target, 2016
Merck & Co., Inc. - Pipeline by Top 10 Route of Administration, 2016
Merck & Co., Inc. - Pipeline by Top 10 Molecule Type, 2016
Merck & Co., Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report